Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

Apollobio: The clinical trial of VGX-3100 is progressing rapidly, and the domestic phase III clinical trial is officially launched! Recently, the VGX-3100 project for cervical precancerous lesions, which was participated in the research and development of the Chinese oncology innovative pharmaceutical company Dongfanglue, has passed new progress. Its domestic phase III clinical trial project has successfully passed the scientific research approval of China Human Genetic Resources International Cooperation and was listed in 2021. The fifth batch of administrative licensing projects for human genetic resources in 2009 means that the VGX-3100 Phase III clinical trial was officially launched in China.

The project is jointly developed by Orient Technology and Inovio Pharmaceuticals, Inc. ( NASDAQ : INO ). Orient Technology has the exclusive right to develop, produce and commercialize VGX-3100 in Greater China (Mainland China, Hong Kong, Macau, Taiwan), and adapt to Symptoms include the treatment and prevention of precancerous lesions of the cervix, vulva and anus caused by HPV infection.

VGX-3100 progress in clinical trials optimistic, had in 2021 Nian 3 Yue 1 Ri, Inovio announced VGX-3100 Shou multicenter, randomized, double-blind, placebo-controlled III clinical trial results on the show, for all subjects evaluable Achieve the primary endpoint of clinical efficacy and all secondary endpoints.

Source: Government Service Platform of the Ministry of Science and Technology

About Dongfang [Apollobio] Strategy

Oriental Strategy focuses on the clinical development and commercialization of innovative oncology drugs, and provides solutions for unmet clinical needs. Currently, it has three new drug platforms, of which the VGX-3100 project is the fastest progressing , and multi-center clinical trials are being carried out in China. . The first indication for this platform is cervical precancerous lesions, and the first ongoing multi-center phase III clinical trial has achieved positive results. If successfully listed, it will be expected to provide the first alternative to surgical resection for tens of millions of patients with HPV infection-related precancerous lesions in China .

The other two indications for anal precancerous lesions and vulvar precancerous lesions are expected to enter Phase III clinical trials in 2021 . In addition, Orient Strategy is also looking for differentiated anti-tumor drug cooperation projects on a global scale through the model of internal development and external cooperation.

https://pz24bkvgtknmlvdgc65qpgp6pq-ac5fdsxevxq4s5y-apollobio-com.translate.goog/newsitem/278565364Inovio